Interesting wording, agree. We do we know:
- Data analysis of the trial commenced in March, so data collection is well and truly finished
- The Company have made it very clear that they are after clinical efficacy, and not statistical significance, so it's not like they plan to "review" to possibly extend the trial in order to increase the sample size.
That being said, "review the status," to me, implies that the trial is still ongoing, which obviously contradicts the above. Is it possible that the data is that promising that a large pharma is coming on board to fund a larger-scale phase 3? I only speculate, but I have heard the CEO is doing the rounds in Europe, and has for the last week or so...
Interesting wording, agree. We do we know: - Data analysis of...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.5¢ |
Change
0.055(20.4%) |
Mkt cap ! $82.30M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 33.5¢ | 27.5¢ | $1.328M | 4.323M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4624 | 32.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 152597 | 4 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |
